Develops and markets over-the-counter pharmaceutical products. Offers a diverse range of personal care products. Now — the numbers.
The stock trades 46% below its peak. The market has trimmed its expectations for the company.
It pays out $0.04 per share each year — regular cash for whoever holds the stock.
The stock sits at $0.78. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back.
Against everything we grade, GNMLF lands somewhere in the middle. The grade moves as the numbers move.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: revenue and profit, the growth trend, the balance sheet, the revenue breakdown.